In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in late 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
IGBA congratulates health Canada for decision on biologics naming that supports growing global consensusGeneva, 27 February 2019 - The International Generic and Biosimilar medicines Association (IGBA) welcomes Health Canada’s decision to proceed with a biologic naming policy that identifies all biologic medicines, including biosimilars, by their unique brand name and non-proprietary (common) name, without… Read More
Statement on the Passing of Dilip ShahFebruary 22, 2019 – Toronto – The following is a statement by Jim Keon, Chair of the International Generic and Biosimilars medicines Association (IGBA), on the passing of Dilip Shah, Secretary-General of the Indian Pharmaceutical Association (IPA). Read More
Suzette Kox nominated as Secretary General of the International Generic and Biosimilar medicines AssociationIGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announces today the nomination of Suzette Kox as Secretary General of the association. Her main role is to coordinate the IGBA activities as… Read More
IGBA Reflection Paper on waiving bridging studies for biosimilar medicines applicationsIGBA proposes a new international biosimilars framework allowing bridging studies to be waived in specific circumstances based on core scientific and regulatory principles established for current products. Read More